Can Bladder Cancer Be Treated Without Removing the Bladder?

Introduction

Bladder cancer is a common malignancy arising in the urinary system. Global estimates from the World Health Organization's International Agency for Research on Cancer (IARC) reflect that bladder cancer accounted for more than 610,000 new diagnoses and approximately 220,000 deaths in 2022, making it one of the ten most frequently diagnosed cancers worldwide.

Receiving a diagnosis of bladder cancer can feel overwhelming, and many patients are concerned about whether treatment will require the complete removal of the bladder. While radical cystectomy (surgical removal of the bladder) remains an important treatment for many cases, advances in cancer care have made bladder-sparing treatment a viable option for selected patients.

Bladder-sparing therapy, also known as bladder preservation therapy, aims to control or eliminate cancer while allowing patients to keep their bladder and maintain natural urinary function. Depending on the stage and characteristics of the cancer, bladder-preserving approaches may involve surgery, chemotherapy, radiation therapy, immunotherapy, or a combination of treatments.

Understanding Bladder Cancer

What Is Bladder Cancer?

Bladder cancer develops when abnormal cells multiply uncontrollably in the lining or deeper layers of the bladder, a hollow pelvic organ that stores urine until it is excreted from the body.

Common risk factors include:

• Smoking
• Exposure to certain industrial chemicals
• Chronic bladder irritation or infections
• Increasing age
• Family history of bladder cancer

Types of Bladder Cancer

There are several types of bladder cancer; some more common than others:

• Urothelial carcinoma (transitional cell carcinoma): The most prevalent type, accounting for the vast majority of bladder cancers.
• Squamous cell carcinoma: Often associated with long-term inflammation or chronic irritation of the bladder.
• Adenocarcinoma: A rare cancer that develops from gland-forming cells within the bladder.
• Small cell carcinoma: A rare yet aggressive variant of bladder cancer.
• Sarcoma: An uncommon cancer arising from connective tissues within the bladder wall.

Stages of Bladder Cancer

For treatment planning, bladder cancer is commonly grouped into two broad categories:

• Non-Muscle-Invasive Bladder Cancer (NMIBC)

The cancer is limited to the bladder's inner lining and has not spread into the bladder muscle.

• Muscle-Invasive Bladder Cancer (MIBC)

The cancer has grown into the bladder's muscular wall. This stage carries a higher risk of spreading to other parts of the body and often requires more intensive treatment.

The stage of bladder cancer plays a major role in determining whether bladder-sparing treatment is appropriate.

Diagnosis

Before deciding on a treatment plan, patients typically undergo a combination of physical examination, cystoscopy, imaging studies (such as CT or MRI), and pathological evaluation of tumor tissue. In selected cases, molecular profiling may also be performed to help guide treatment decisions.

What Is Bladder-Sparing Therapy?

Bladder-sparing therapy refers to treatment approaches designed to control bladder cancer while preserving the patient's bladder.

Unlike radical cystectomy, which removes the entire bladder and requires an alternative method for urine drainage, bladder preservation seeks to maintain normal bladder function whenever possible.

Bladder preservation therapy for bladder cancer may involve:

• Transurethral resection of bladder tumor (TURBT)
• Intravesical therapy
• Partial cystectomy
• Trimodal therapy (TMT)
• Emerging immunotherapy-based approaches in selected patients

Not every patient is a candidate for bladder preservation, but for carefully selected individuals, these approaches may offer excellent cancer control while maintaining quality of life.

For medically fit patients with muscle-invasive bladder cancer (MIBC), the standard treatment has traditionally been radical cystectomy (complete bladder removal along with nearby lymph nodes), which is often preceded by neoadjuvant chemotherapy to shrink the tumor, eliminate microscopic cancer cells, and improve long-term survival.

Clinical studies suggest that approximately 25–30% of patients with muscle-invasive bladder cancer may be suitable candidates for bladder-preserving treatment after comprehensive evaluation by a multidisciplinary team, while the majority still require radical cystectomy because of extensive, multifocal, or aggressive disease.

Who Is a Candidate for Bladder-Sparing Treatment?

Suitability depends on multiple factors, including tumor characteristics, overall health, and patient preferences.

Potential candidates may include:

• Patients with localized bladder cancer
• Individuals with a single tumor rather than multiple tumors
• Patients with good bladder function
• Patients without extensive carcinoma in situ (a flat, high-grade form of cancer confined to the bladder lining)
• Individuals who may not be medically fit for major surgery
• Selected patients with muscle-invasive bladder cancer who meet strict clinical criteria

A multidisciplinary team, including urologists, radiation oncologists, and medical oncologists, typically evaluates whether bladder preservation is appropriate.

Bladder-Sparing Treatment Approaches

Transurethral Resection of Bladder Tumor (TURBT)

TURBT is one of the most common procedures used in bladder cancer treatment.

What is TURBT?

Transurethral Resection of Bladder Tumor, or TURBT for short, is the most common minimally invasive procedure employed to diagnose and treat non-muscle-invasive bladder cancer (NMIBC). Sometimes referred to as a “scraping” surgery, it removes visible tumors from the bladder without making any external incisions.

How is TURBT performed?

The procedure is usually carried out under general or spinal anesthesia and typically takes 30 to 90 minutes, depending on the size and number of tumors. A surgeon passes a thin tube called a cystoscope through the urethra into the bladder. The cystoscope contains a camera that allows the surgeon to examine the bladder lining. A small wire loop or probe is then used to carefully remove the tumor and seal blood vessels using heat to reduce bleeding.

In some centers, advanced imaging techniques such as narrow-band imaging (NBI) or photodynamic diagnosis (blue-light cystoscopy) may be used to help detect small or flat tumors that might otherwise be missed.

When is TURBT used?

TURBT plays a central role in diagnosing, staging, and treating early-stage bladder cancer. Following the procedure, some patients receive a single dose of intravesical chemotherapy directly into the bladder to reduce the risk of recurrence.

Because bladder cancer can recur, more than one TURBT may be needed over time, either to remove new tumors or to ensure all cancer has been completely removed. However, TURBT alone is generally not sufficient for most muscle-invasive bladder cancers, where additional treatments such as trimodal therapy or radical cystectomy are usually recommended.

What to expect after TURBT surgery

Most patients return home the same day or after a short hospital stay.

Common temporary symptoms

• Mild bleeding in the urine
• A burning sensation during urination
• Increased urinary frequency

How long does it take to recover from TURBT surgery?

Recovery typically occurs over several days to a few weeks.

Potential TURBT complications

Although generally safe, complications may include:

• Bleeding
• Infection
• Bladder perforation
• Urinary symptoms
• Rarely, TUR syndrome, a fluid imbalance caused by the absorption of irrigation fluid during surgery

Intravesical Therapy (BCG or Intravesical Chemotherapy)

Intravesical therapy involves placing medication directly into the bladder through a thin catheter rather than giving it by mouth or through a vein. This allows high concentrations of the drug to act on the bladder lining while limiting exposure to the rest of the body.

When is it used?

Intravesical therapy is commonly used after TURBT for patients with non-muscle-invasive bladder cancer, particularly those at intermediate or high risk of recurrence. It helps destroy any remaining cancer cells and reduces the likelihood of the cancer returning or progressing.

Types of Intravesical Therapy

The two main types are:

• BCG (Bacillus Calmette-Guérin): An immunotherapy that stimulates the immune system to attack cancer cells.
• Intravesical chemotherapy: Chemotherapy drugs, such as mitomycin C or gemcitabine, are placed directly into the bladder to destroy residual cancer cells.

Treatment is usually given as a series of outpatient sessions over several weeks, with some patients receiving maintenance therapy for months or years depending on their risk profile.

Intravesical therapy is not effective for muscle-invasive or metastatic bladder cancer, as these cancers extend beyond the bladder lining and require more extensive treatment, such as surgery, systemic chemotherapy, radiation therapy, or combinations of these approaches.

Recovery and side effects

Most patients are treated on an outpatient basis.

Possible side effects include:

• Frequent urination
• Burning sensation during urination
• Blood in the urine
• Fatigue
• Flu-like symptoms, particularly with BCG

Partial Cystectomy

Partial cystectomy removes only the affected part of the bladder containing the tumor while preserving the remaining portion.

When is a Partial Cystectomy considered?

This procedure is suitable for only a small number of patients, typically when:

• The tumor is localized
• The cancer is located in a favorable area
• Complete removal with adequate margins is possible

How is it performed?

Partial cystectomy may be performed using:

• Traditional open surgery
• Laparoscopic techniques
• Robotic-assisted surgery

Recovery

Patients generally require a hospital stay and several weeks of recovery.

Potential side effects include:

• Urinary symptoms
• Infection
• Bleeding
• Reduced bladder capacity in some cases

Although partial cystectomy allows patients to retain their bladder, it is suitable for only a small proportion of bladder cancers. Studies have reported five-year overall survival rates of approximately 45% to 70% in carefully selected patients, although recurrence within the remaining bladder can occur, making lifelong surveillance with cystoscopy essential.

For patients with muscle-invasive bladder cancer, cisplatin-based neoadjuvant chemotherapy may be given before surgery to shrink the tumor and improve long-term survival.

Trimodal Therapy (TMT)

Trimodal or trimodality therapy is one of the most important bladder-preserving approaches for selected patients with muscle-invasive bladder cancer.

What is Trimodal Therapy?

Trimodal bladder preservation therapy combines:

1. Maximal TURBT
2. Chemotherapy
3. Radiation therapy

The goal is to eliminate cancer while preserving the bladder.

How is it given?

The tumor is first removed as completely as possible through TURBT.

After maximal tumor removal, patients receive radiation therapy together with chemotherapy, which increases the sensitivity of cancer cells to radiation. In selected patients, cisplatin-based neoadjuvant chemotherapy may also be given before chemoradiation to treat microscopic disease and improve outcomes.

Potential side effects

Possible side effects include:

• Fatigue
• Urinary urgency and frequency
• Diarrhea
• Bladder irritation
• Temporary bowel symptoms
• Chemotherapy-related adverse effects

Benefits of Bladder-Sparing Therapy

Preserving Quality of Life

For many patients, keeping the bladder can significantly affect daily life and emotional well-being.

Potential advantages include:

• Maintaining natural urination
• Avoiding urinary diversion procedures
• Avoiding an external urostomy bag
• Preserving body image
• Maintaining independence in daily activities

For some patients, preserving the bladder may also help avoid practical, cultural, or religious challenges associated with living with a stoma. For example, some individuals report concerns about stoma care during prayer, fasting, and ritual purification, highlighting the importance of discussing personal preferences and values when choosing a treatment approach.

Shorter Recovery in Selected Cases

Many bladder-preserving procedures are less invasive than radical cystectomy and may involve shorter recovery periods.

Comparable Outcomes in Carefully Selected Patients

Modern studies suggest that selected patients undergoing bladder-preserving treatment, particularly trimodal therapy, can achieve favorable long-term outcomes while maintaining bladder function.

Potential Risks and Limitations

Bladder preservation is not without challenges.

Potential limitations include:

• Risk of cancer recurrence
• Need for ongoing monitoring
• Urinary frequency or urgency
• Bleeding
• Radiation-related side effects
• Chemotherapy-related toxicity

Some patients may ultimately require salvage cystectomy, which is bladder removal performed after initial bladder-preserving treatment has not achieved adequate cancer control.

Comparison of Bladder-Sparing Treatment Approaches and Radical Cystectomy

Outcomes, Success Rates, and Follow-Up Care

Cancer Control Outcomes

Outcomes depend on:

• Cancer stage
• Tumor characteristics
• Patient selection
• Treatment quality
• Adherence to follow-up

Evidence continues to support bladder preservation as an effective option for selected patients, particularly those receiving modern trimodal therapy.

Bladder-sparing treatment can provide excellent cancer control in carefully selected patients, particularly those with muscle-invasive bladder cancer treated with trimodal therapy. Studies have reported complete response rates of approximately 70–80% following trimodal therapy, with many patients achieving long-term bladder preservation.

Recent systematic reviews have also found that overall survival (five-year overall survival rates approaching 50–60%), disease-free survival, and local recurrence-free survival are comparable to radical cystectomy in appropriately selected patients, highlighting bladder preservation as a safe and effective alternative for some individuals.

Functional Outcomes

Many patients retain good bladder function and continue to urinate normally after successful bladder-preserving treatment. Quality-of-life outcomes are often favorable because the bladder is preserved, although urinary and sexual function may vary depending on the treatment received.

Long-Term Surveillance

Bladder-sparing treatment requires lifelong surveillance because bladder cancer can recur, even years after treatment. Follow-up typically includes regular cystoscopy, urine tests, imaging scans, and clinical examinations. Early detection of recurrence allows prompt treatment, and in some cases, salvage radical cystectomy may be recommended if the cancer returns or persists.

Lifestyle and Supportive Care

Patients can support recovery and long-term health by:

• Avoiding tobacco use
• Maintaining a healthy weight
• Staying physically active
• Adhering to follow-up schedules
• Reporting new symptoms promptly

Advanced and Emerging Technologies in Bladder Preservation

Research continues to expand treatment possibilities for bladder preservation.

Precision Radiation Therapy

Advances in image-guided radiation therapy are improving treatment precision while limiting radiation exposure to surrounding healthy tissues. Technologies such as MR-Linac systems, CyberKnife, proton therapy, and TrueBeam enable more accurate tumor targeting and may improve outcomes for selected patients.

Precision Oncology

Precision oncology uses molecular profiling and biomarkers to better understand the biology of an individual's tumor and guide personalized treatment decisions.

Recent studies, including the DUTRENEO trial, have evaluated whether biomarker-guided approaches can identify patients most likely to benefit from neoadjuvant chemotherapy and immunotherapy (although results have been inconclusive), supporting the development of a more individualized treatment approach.

Immunotherapy and Combination Approaches

Immune checkpoint inhibitors are reshaping the treatment of bladder cancer. Researchers are investigating combinations of immunotherapy with chemotherapy and radiation therapy to improve cancer control while preserving the bladder.

A recent advancement is Durvalumab plus BCG, FDA-approved in 2026 for selected patients with high-risk NMIBC after TURBT. The Phase III POTOMAC trial involving this combination therapy demonstrated improved disease-free survival compared with BCG alone.

Robotic and Minimally Invasive Techniques

Advances in robotic surgery, including robotic platforms such as the da Vinci Surgical System, facilitate improved precision and faster recovery for selected procedures, including partial cystectomy. Studies suggest that robotic-assisted surgery can achieve cancer control comparable to open surgery while reducing blood loss and shortening hospital stays in appropriately selected patients.

When Bladder Removal May Still Be Recommended

Despite advances in bladder preservation, radical cystectomy remains the preferred treatment in many situations.

Bladder removal may be recommended for:

• Large tumors
• Multiple tumors throughout the bladder
• Extensive carcinoma in situ
• Aggressive or recurrent disease
• Poor bladder function
• Cases where bladder-preserving treatment is unlikely to provide adequate cancer control

The goal is always to select the treatment strategy that offers the best balance between cancer control, quality of life, and long-term outcomes.

Frequently Asked Questions

Are there non-surgical options for bladder preservation?

Yes. Depending on the cancer stage, treatment may involve intravesical therapy, chemotherapy, radiation therapy, immunotherapy, or combinations of these approaches.

Is it advisable to get a second opinion for bladder-sparing treatment plans?

Yes. Since bladder preservation decisions can be complex, consulting a multidisciplinary team for a second opinion can help patients better understand the full range of available options.

Can painful bladder symptoms occur after treatment?

Yes, many patients experience urinary urgency, frequency, or bladder discomfort in the weeks after treatment, and these acute symptoms usually improve as the bladder recovers. However, some patients may develop long-term complications such as radiation cystitis, so persistent symptoms should be discussed with the healthcare team.

 

References:

Show All ▼

 

Disclaimer